- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06179407
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
April 4, 2024 updated by: Merck Sharp & Dohme LLC
A Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Sleep Latency Effects of MK-6552 in Participants With Narcolepsy Type 1
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1).
Part 1 will evaluate safety, tolerability, and PK of MK-6552 after administration of ascending doses in a single day to support a dose level decision for Part 2. Part 2 will investigate the PD of MK-6552 after single-day and multiple-day administration.
Participants who complete Part 1 and demonstrate that they are able to tolerate at least one dose level of MK-6552 will participate in Part 2.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Toll Free Number
- Phone Number: 1-888-577-8839
- Email: Trialsites@merck.com
Study Locations
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80915
- Recruiting
- Delta Waves, Inc. ( Site 0008)
-
Contact:
- Study Coordinator
- Phone Number: 719-262-9283
-
-
Florida
-
Brandon, Florida, United States, 33511
- Recruiting
- Teradan Clinical Trials, LLC ( Site 0005)
-
Contact:
- Study Coordinator
- Phone Number: 813-758-6613
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Recruiting
- NeuroTrials Research Inc ( Site 0006)
-
Contact:
- Study Coordinator
- Phone Number: 404-851-9934
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
- Recruiting
- Bogan Sleep Consultants ( Site 0001)
-
Contact:
- Study Coordinator
- Phone Number: 803-251-3093
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Has a diagnosis of NT1, including a valid polysomnography within the previous 5 years and a current diagnosis of NT1 for at least 6 months based on criteria established by the International Classification of Sleep Disorders- Third Edition, or Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [American Psychiatric Association 2013]
- Is positive for HLA-DQB1*06:02 allele supporting a diagnosis of NT1
- Has a baseline history of unequivocal cataplexy prior to initiation of anti-cataplexy medications
- Reports a total sleep time of > 6 hours on at least 4 out of 7 nights each week within the 4 weeks prior to screening visit
Exclusion Criteria:
- Has history of or current hypertension
- Has underlying cardiovascular or cerebrovascular conditions in which an acute rise in blood pressure would pose a clinical concern, including but nor limited to aneurysms or arteriovenous malformations
- Has a history of renal or hepatic impairment
- Has a history of cardiac ischemia or cerebral ischemia including but not limited to history of stroke, transient ischemic attack, or transient global amnesia
- Based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale, is at imminent risk of self-harm or of harm to others in the opinion of the investigator
- Mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years
- History of cancer (malignancy)
- Has a history of any of the following sleep disorders: obstructive sleep apnea (OSA) defined as an Apnea Hypopnea Index > 15 per hour per the American Academy of Sleep Medicine alternate criteria, primary insomnia (within the past 6 months), circadian rhythm sleep disorder, shift work sleep disorder (within the past 6 months), clinically significant parasomnia at the discretion of the investigator
- Has a history of seizure disorder, clinically significant head trauma, or past invasive intracranial surgery or clinically significant dementia
- Positive test(s) for Hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MK-6552
In Part 1, participants will receive single oral doses of MK-6552 in ascending fashion approximately 6 hours apart for a single day, based on safety and tolerability of the previous dose.
In Part 2, participants will receive multiple days of MK-6552 dosing (7 consecutive days) at the highest safe and well tolerated MK-6552 dose determined on an individual basis from Part 1.
|
Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
|
Placebo Comparator: Placebo
In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
|
In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants experiencing an Adverse Event (AE)
Time Frame: Up to approximately 7 weeks
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
The number of participants that experience an AE will be reported.
|
Up to approximately 7 weeks
|
Number of participants discontinuing study intervention due to an Adverse Event (AE)
Time Frame: Up to approximately 5 weeks
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
The number of participants that discontinue study intervention due to an AE will be reported.
|
Up to approximately 5 weeks
|
Sleep Onset Latency Measured by the Maintenance of Wakefulness Test (MWT)
Time Frame: 1 hour after each dose on Day 7
|
The MWT is a daytime polysomnographic procedure that measures objectively the ability to remain awake during sleep-inducing circumstances.
Sleep onset latency is defined as the first occurrence of sustained sleep (i.e. 3 consecutive 30 second epochs of N1 [stage 1] sleep or any single 30 second epoch of N2 [stage 2], N3 [stage 3 and 4 combined] or REM).
The primary outcome measure of sleep onset latency measured by the MWT on Day 7 will be reported.
|
1 hour after each dose on Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Plasma Concentration-Time Curve of MK-6552 from Time Zero to infinity (AUC0-inf)
Time Frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Blood samples will be collected at specified intervals for the determination of AUC0-inf.
AUC0-inf is defined as the area under the concentration-time curve of MK-6552 from time zero to infinity and will be reported for participants in Part 1.
|
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Area Under the Plasma Concentration-Time Curve of MK-6552 from Time Zero to 24 hours postdose (AUC0-24)
Time Frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Blood samples will be collected at specified intervals for the determination of AUC0-24.
AUC0-24 is defined as the area under the concentration-time curve of MK-6552 from time zero to 24 hours postdose and will be reported for participants in Part 1.
|
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Time to Maximum Concentration (Tmax) of MK-6552
Time Frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Blood samples will be collected at specified intervals for the determination of Tmax.
Tmax is defined as the time to the maximum concentration of MK-6552 reached and will be reported for participants in Part 1.
|
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Maximum Concentration (Cmax) of MK-6552
Time Frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Blood samples will be collected at specified intervals for the determination of Cmax.
Cmax is defined as the maximum concentration of MK-6552 reached and will be reported for participants in Part 1.
|
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Concentration of MK-6522 at 2 Hours Postdose (C2h)
Time Frame: Day 1: 2 hours postdose
|
Blood samples will be collected at specified intervals for the determination of C2h.
C2h is defined as the concentration of MK-6552 reached at 2 hours postdose and will be reported for participants in Part 1.
|
Day 1: 2 hours postdose
|
Concentration of MK-6522 at 6 Hours Postdose (C6h)
Time Frame: Day 1: 6 hours post Dose 1
|
Blood samples will be collected at specified intervals for the determination of C6h.
C6h is defined as the concentration of MK-6552 reached at 6 hours post Dose 1 and will be reported for participants in Part 1.
|
Day 1: 6 hours post Dose 1
|
Concentration of MK-6522 at 18 Hours Postdose (C18h)
Time Frame: 18 hours post Day 1 Dose 2
|
Blood samples will be collected at specified intervals for the determination of C18h.
C18h is defined as the concentration of MK-6552 reached at 18 hours post Dose 2 and will be reported for participants in Part 1.
|
18 hours post Day 1 Dose 2
|
Apparent Oral Clearance (CL/F) of MK-6552
Time Frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Blood samples will be collected at specified intervals for the determination of CL/F.
CL/F is defined as the rate at which MK-6552 is completely removed from plasma and will be reported for participants in Part 1.
|
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Apparent Volume of Distribution (Vz/F) of MK-6552
Time Frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Blood samples will be collected at specified intervals for the determination of Vz/F.
Vz/F is defined as the theoretical volume that would be necessary to contain the total amount of administered MK-6522 at the same concentration that it is observed in the blood plasma, and will be reported for participants in Part 1.
|
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Apparent Terminal Half-life (t½) of MK-6552
Time Frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Blood samples will be collected at specified intervals for the determination of t½.
t½ is defined as the time required to divide the MK-6552 plasma concentration by two after reaching pseudo-equilibrium, and will be reported for participants in Part 1.
|
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2024
Primary Completion (Estimated)
December 5, 2024
Study Completion (Estimated)
December 5, 2024
Study Registration Dates
First Submitted
December 12, 2023
First Submitted That Met QC Criteria
December 12, 2023
First Posted (Actual)
December 21, 2023
Study Record Updates
Last Update Posted (Actual)
April 5, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6552-004
- MK-6554-004 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Narcolepsy
-
University of Dublin, Trinity CollegeSt. James's Hospital, IrelandSuspendedNarcolepsy | Hypersomnolence | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy 1 | Narcolepsy and HypersomniaIreland
-
Northwestern UniversityActive, not recruitingNarcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy Type 2United States
-
Northwestern UniversityNot yet recruitingNightmare | Narcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Nightmare Disorder With Associated Other Sleep Disorder
-
NLS PharmaceuticsCompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
Boston Children's HospitalAmerican Academy of Sleep MedicineRecruitingIdiopathic Hypersomnia | Narcolepsy Type 1 | Narcolepsy Type 2United States
-
NLS PharmaceuticsNot yet recruitingNarcolepsy Type 1 | Narcolepsy With Cataplexy
-
TakedaRecruitingNarcolepsy Type 1 | Narcolepsy Type 2Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
-
Northwestern UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
BioprojetActive, not recruitingNarcolepsy Without Cataplexy | Narcolepsy With CataplexyFrance, Italy, Russian Federation, Finland, Netherlands
-
TakedaTerminatedNarcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
Clinical Trials on MK-6552
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus
-
Merck Sharp & Dohme LLCCompletedHypertension | Isolated Systolic Hypertension (ISH)
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHepatitis C Virus Infection
-
Merck Sharp & Dohme LLCCompletedSolid TumorsUnited States, Canada, Switzerland
-
Merck Sharp & Dohme LLCRecruitingPulmonary Arterial Hypertension | Hypertension, PulmonaryUnited States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
-
Merck Sharp & Dohme LLCCompleted